Check out our press release hub, powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop here.
Clinical data presented from the podium at 5th Annual Meeting of the Cervical Spine Research Society–Asia Pacific (CSRS-AP)
PARIS & SAN FRANCISCO–(BUSINESS WIRE)–April 29, 2014–
SpineGuard (FR0011464452 – ALSGD), an innovative medical device company focused on improving spine surgery safety, announced today that the anticipation of pedicle breaches using its FDA-cleared and CE-marked PediGuard® device in a prospective clinical analysis of 50 patients with “rather rare and severe cervical spine disease” was 100% accurate in identifying an impassable cortical pedicle isthmus in 34 pedicles. The data was presented by principal investigator Heiko Koller, MD, PhD, at the 5th Annual Meeting of CSRS-AP in Ho Chi Minh City, Vietnam. In 34 pedicles a decision to stop pedicle screw tract preparation based on a signal from the PediGuard device that suggested an impassable cortical stimulus isthmus was later confirmed appropriate based on analysis of postoperative CT scans.
« We surgeons are constantly faced with difficult treatment planning for complex cervical deformities. By integrating the PediGuard device into surgery, we are able to provide our patients with greater construct stability, less neurological risk, and a better overall surgical outcome, » said Dr. Koller, Werner Wicker Klinik, Bad Wildungen – Germany.
By far, pedicle screws are the most common implant used in spinal surgery. Unfortunately, high rates of pedicle screw misplacements in the vertebra persist, which can lead to dramatic neurologic and vascular impairment. The scientific literature reveals that about 20% of pedicle screws are misplaced using conventional techniques, causing a 2% to 9% overall complication rate. Several published clinical studies in peer-reviewed medical journals have demonstrated the excellent pedicle screw placement accuracy of PediGuard®.
About the PediGuard® Bone-Monitoring Platform
Co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer, PediGuard is the world’s first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches. Real-time feedback is provided via audio and visual signals. Over 30,000 procedures have been performed with PediGuard on all continents. Several studies published in peer-reviewed medical and scientific journals have demonstrated that PediGuard detects 98% of pedicle breaches, presents an average screw placement accuracy of 97% (vs. 92% on average for navigation), provides 3-fold less pedicle perforations than with free-hand technique and a 3-fold reduction in neuro-monitoring alarms. It also limits radiation exposure by 25-30% and decreases by 15% the time for pedicle screw placement.
Co-founded in 2009 by Pierre Jérôme and Stéphane Bette, former executives at Medtronic Sofamor-Danek and SpineVision, SpineGuard’s primary objective is to establish its FDA-cleared and CE-marked PediGuard® device as the global standard of care for safer screw placement in spine surgery. SpineGuard’s mission is to make spine surgery safer. The company has offices in San Francisco and Paris. For further information, visit www.spineguard.com.
The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.
Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1-508-359-4005, x108
Pierre Jérôme, CEO, +33 (0) 1 45 18 45 19
VentureBeat’s VB Insight team is studying email marketing tools.
Chime in here, and we’ll share the results